Savara (SVRA) EBITDA Margin (2013 - 2020)

Savara (SVRA) posted quarterly EBITDA Margin of 1301200.0% for Q4 2020, down 30786.16% quarter-over-quarter from 4212.89% in Q3 2020.

Savara (SVRA) EBITDA Margin (2013 - 2020) Analysis & Trends

Savara (SVRA) has reported EBITDA Margin for 5 consecutive years, with 1301200.0% the latest figure, recorded in Q4 2020.

In Q4 2020, EBITDA Margin changed N/A year-over-year to 1301200.0%; the TTM figure through Mar 2022 stood at 3910900.0% (changed N/A YoY), while the FY2020 annual figure was 19182.88%, changed N/A from the prior year.
EBITDA Margin declined to 1301200.0% in Q4 2020 per SVRA's latest filing, from 4212.89% in the prior quarter.
Across five years, EBITDA Margin topped out at 9939.36% in Q2 2017 and bottomed at 1301200.0% in Q4 2020.
Historically, EBITDA Margin has averaged 218123.51% across 3 years, with a median of 4645.81% in 2017.
On a YoY basis, EBITDA Margin climbed as much as 1697789 bps in 2016 and fell as far as 1697789 bps in 2016.
Savara's EBITDA Margin stood at 1011.0% in 2016, then soared by 1083 bps to 9939.36% in 2017, then slumped by 13191 bps to 1301200.0% in 2020.
Business Quant data shows SVRA's EBITDA Margin at 1301200.0% in Q4 2020, 4212.89% in Q3 2020, and 9939.36% in Q2 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	30.15%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	31.68%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	19.06%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-77,569,866.34%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	19.75%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	17.93%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-0.36%
10	Savara	1.11 Bn	1.11 Bn	-	-

Download Data